WuXi PharmaTech Listed among Asia’s Fastest Growing Companies, Third Year Running

Shanghai - China, 14 December 2006
WuXi PharmaTech, China's leading provider of pharmaceutical R&D outsourcing services announced today that it has been named 173rd on the Deloitte Fast 500 Asian. This is the third consecutive year the pharmaceutical service company has received the prestigious award, placing it in an elite group of only 58 companies

The Deloitte Touche Tohmatsu (Deloitte) Technology Fast 500 Asia Pacific award is Asia's most objective industry-ranking standard, focusing specifically on the technology sector. The award was first introduced in 2001 to recognize the most exceptional of Asia's 500 fastest-growing technology companies from industries including all areas of technology, ranging form internet based companies to biotechnology. The 2006 list, like years prior, is a mixture of both public and private companies.

This year's 173rd ranking represents a 244% 3-year annual growth rate for the pharmaceutical service company. WuXi PharmaTech is among only 58 companies to be recognized for a third consecutive year.

"We are honored to have our success once again recognized," commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "It is a great encouragement and satisfaction to be listed alongside prominent companies such as Infosys of India and others who have been selected for a third consecutive year. This designation reflects highly on WuXi PharmaTech's commitment to quality of service, high operating standards, and transparency," continued Dr. Li.

About WuXi PharmaTech
Founded in 2001, Shanghai-based WuXi PharmaTech is China's leading drug R&D service company. As a research-driven and customer-focused company, WuXi PharmaTech offers global pharmaceutical and biopharmaceutical companies a diverse, value-added, and fully integrated portfolio of outsourcing services ranging from discovery chemistry, service biology to bioanalytical chemistry, from process chemistry to large scale GMP manufacturing. WuXi PharmaTech assists its global partners in shorting the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save our clients both time and money. Currently, our client list consists of 19 of the top 20 pharmaceutical, and 8 of the top 10 biopharmaceutical companies. For more information please visit www.pharmatechs.com.

About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respective subsidiaries and affiliates. Deloitte Touche Tohmatsu is an organization of member firms around the world devoted to excellence in providing professional services and advice, focused on client service through a global strategy executed locally in nearly 150 countries. With access to the deep intellectual capital of 135,000 people worldwide, Deloitte delivers services in four professional areas—audit, tax, consulting, and financial advisory services—and serves more than one-half of the world's largest companies, as well as large national enterprises, public institutions, locally important clients, and successful, fast-growing global growth companies. For more information please visit http://www.deloitte.com.